Dear Colleagues,

Alzheimer’s disease is the most common form of dementia, which worsens as it progresses and eventually leads to death. AD is associated with the formation of β-amyloid plaques and neurofibrillary tangles in the brain. However, findings have shown that the accumulation of Aβ plaques is not sufficient to cause the disease. In this regard, growing evidence suggests that acute inflammation may play a pivotal role in brain function, promoted by astrocytes activation and the production of proinflammatory markers. Despite the great effort made hitherto, there is no effective therapeutic strategy that is capable of stopping or reverting the disease’s progress because of the low drug solubility, rapid metabolism, or inability to cross the blood–brain barrier to reach brain parenchyma. Therefore, many molecule drugs obtained to tackle this disease tend to ameliorate or delay its course and, as a result, finding new therapies for treating Alzheimer’s disease and other dementias remains a challenge. For this reason, numerous strategies have been described that rely on targeting ApoE, tau, Aβ, or neurotoxic events, among others, by evaluating their effects on specific downstream proteins.

Nanotechnology has emerged as an important tool for the treatment a plethora of diseases including neurological disorders. Nanoparticles have displayed great potential for encapsulating small molecule drugs, in addition to their ability to cross the blood–brain barrier, making nanomaterials a possibility for the treatment of Alzheimer’s disease.

This Special Issue of the journal Pharmaceutics aims to publish reviews, original research articles, and communications in order to improve our understanding of the therapeutic strategies of nanomaterials in the field of Alzheimer’s disease and other dementias.

Dr. Santiago Grijalvo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Alzheimer’s disease
• Dementia
• Drug delivery systems
• Nanomedicine
• Nanotechnology
• Therapy